Search Results - "Tomaka, F."

Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV‐1‐infected treatment‐naïve patients in the ARTEMIS trial by Orkin, C, DeJesus, E, Khanlou, H, Stoehr, A, Supparatpinyo, K, Lathouwers, E, Lefebvre, E, Opsomer, M, Van de Casteele, T, Tomaka, F

“…Objective This paper presents the final analysis of once‐daily darunavir/ritonavir (DRV/r) vs. lopinavir/ritonavir (LPV/r) in treatment‐naïve HIV‐1‐infected…”
Get full text

Etravirine in treatment‐experienced, HIV‐1‐infected children and adolescents: 48‐week safety, efficacy and resistance analysis of the phase II PIANO study by Tudor‐Williams, G, Cahn, P, Chokephaibulkit, K, Fourie, J, Karatzios, C, Dincq, S, Opsomer, M, Kakuda, TN, Nijs, S, Tambuyzer, L, Tomaka, FL

“…Objectives PIANO (Paediatric study of Intelence As an NNRTI Option; TMC125‐C213; NCT00665847) assessed the safety/tolerability, antiviral activity and…”
Get full text

Subgroup analysis of virological response rates with once‐ and twice‐daily darunavir/ritonavir in treatment‐experienced patients without darunavir resistance‐associated mutations in the ODIN trial by Sension, M, Cahn, P, Domingo, P, Hodder, S, Opsomer, M, Lathouwers, E, Van de Casteele, T, Tomaka, F

“…Background ODIN (once‐daily darunavir in treatment‐experienced patients) was a 48‐week, phase III, randomized, open‐label trial comparing once‐daily (qd)…”
Get full text

Effects of ritonavir‐boosted darunavir vs. ritonavir‐boosted atazanavir on lipid and glucose parameters in HIV‐negative, healthy volunteers by Tomaka, F, Lefebvre, E, Sekar, V, Van Baelen, B, Vangeneugden, T, Vandevoorde, A, Diego Miralles, G

“…Background Darunavir (TMC114) is a new HIV protease inhibitor (PI). Design This Phase I, randomized, open‐label trial compared the effects of darunavir plus…”
Get full text

Model‐Based Once‐Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV‐1‐Infected Patients Aged ≥3 to <12 Years by Brochot, A, Kakuda, TN, Van De Casteele, T, Opsomer, M, Tomaka, FL, Vermeulen, A, Vis, P

“…An existing population pharmacokinetic model of darunavir in adults was updated using pediatric data from two studies evaluating weight‐based, once‐daily…”
Get full text

1150 A COMPREHENSIVE REVIEW OF PATTERNS OF VIRAL LOAD DECLINE IN PATIENTS TREATED WITH TELAPREVIR PLUS PEGINTERFERON AND RIBAVIRIN by Picchio, G, De Meyer, S, Dierynck, I, Ghys, A, Gritz, L, Kieffer, T.L, Bartels, D.J, Tomaka, F, Bengtsson, L, Luo, D, Jacobson, I.M, Kauffman, R.S, Adda, N, Sarrazin, C

Get full text

55 FUTILITY RULES IN TELAPREVIR COMBINATION TREATMENT by Jacobson, I.M, Bartels, D.J, Gritz, L, Kieffer, T.L, De Meyer, S, Tomaka, F, Bengtsson, L, Luo, D, Adiwijaya, B.S, Kauffman, R.S, Picchio, G, Adda, N

Get full text

T-26 Long-term FU of patients with CHC treated with telaprevir in combination with PEG-IFN alfa-2a and RBV: Interim analysis of the EXTEND study by Alberti, A, Zeuzem, S, Sulkowski, M.S, Zoulim, F, Sherman, K.E, Wei, L.J, van Baelen, B, Sullivan, J, Kieffer, T.L, De Meyer, S, Picchio, G, Tomaka, F, Graham, C, McHutchison, J.G

Get full text

HTA91 Health Impact of a Potential HIV Vaccine Among Men Who Have Sex with Men in the United States by Ayer, T., Merdan, S., Oriol Mathieu, V., Van Effelterre, T., Yildirim, I., Tomaka, F., Pau, M., Bookhart, B., Chhatwal, J., El Khoury, A.C.

Get full text

Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96 by ARASTEH, Keikawus, YENI, Patrick, POZNIAK, Anton, GRINSZTEJN, Beatriz, JAYAWEERA, Dushyantha, ROBERTS, Afsoon, HOY, Jennifer, DE MEYER, Sandra, VANGENEUGDEN, Tony, TOMAKA, Frank

“…Long-term (96-week) efficacy and safety of the protease inhibitor (PI) darunavir coadministered with low-dose ritonavir (DRV/r) was evaluated in HIV type-1…”
Get full text

Idiopathic midesophageal stricture : A new cause of dysphagia in a patient with AIDS by SHAPIRO, B. D, EHRENPREIS, E. D, TOMAKA, F. L, BONNER, G. F, SECREST, K. M, CHENEY, L. M

“…A number of disorders may result in the complaint of dysphagia in HIV-infected patients. These include fungal, viral, bacterial, parasitic, medication-induced,…”
Get full text

GAM analysis of the relationship between DRV PK and pharmacodynamics following DRV/r 800/100 mg qd in the phase III trials ARTEMIS and ODIN by Kakuda, T, Tomaka, F, Van De Casteele, T, Vangeneugden, T

“…Background Once‐daily (qd) darunavir/ritonavir (DRV/r) 800/100mg was evaluated in two randomised and controlled Phase III trials, showing high response rates…”
Get full text

Effect of Ritonavir-Boosted Tipranavir or Darunavir on the Steady-State Pharmacokinetics of Elvitegravir by Mathias, Anita A, Hinkle, John, Shen, Gong, Enejosa, Jeff, Piliero, Peter J, Sekar, Vanitha, Mack, Rebecca, Tomaka, Frank, Kearney, Brian P

“…OBJECTIVE:Elvitegravir (EVG) is in phase 3 development in combination with ritonavir (RTV)-boosted protease inhibitors in treatment-experienced, HIV-infected…”
Get full text

Influence of demographic and disease parameters on virological response to once‐ vs twice‐daily darunavir/ritonavir (DRV/r) at week 48 in ODIN by Sension, M, Arns Da Cunha, C, Domingo, P, Supparatpinyo, K, Van De Casteele, T, De Doncker, P, Tomaka, F

“…7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK…”
Get full text

Phase III TITAN week 96 final analysis: efficacy/safety of darunavir/r (DRV/r) vs. lopinavir/r (LPV/r) in LPV-naïve, treatment-experienced patients by Bánhegyi, D, Katlama, C, Da Cunha, C, Schneider, S, Rachlis, A, Romanenko, O, Workman, C, Vandevoorde, A, Tomaka, F, Vangeneugden, T, Spinosa-Guzman, S

Get full text

O424 Resistance development in virological failures with DRV/r or LPV/r: 96-week analysis of the Phase III TITAN trial in treatment-experienced patients by De Meyer, S, Lathouwers, E, Dierynck, I, De Paepe, E, Van Baelen, B, Vangeneugden, T, Tomaka, F, de Béthune, MP, Picchio, G

Get full text

Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged ≥ 3 to <12 Years: Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations by Brochot, A, Kakuda, TN, Van De Casteele, T, Opsomer, M, Tomaka, FL, Vermeulen, A, Vis, P

Get full text

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial by Madruga, J V, Berger, D, McMurchie, M, Suter, F, Banhegyi, D, Ruxrungtham, K, Norris, D, Lefebvre, E, de Bethune, M-P, Tomaka, F, De Pauw, M, Vangeneugden, T, Spinosa-Guzman, S

“…Background The protease inhibitor darunavir has been shown to be efficacious in highly treatment-experienced patients with HIV infection, but needs to be…”
Get full text